Therapy Areas
Latest News
Roche secures IVDR approval to expand VENTANA MMR RxDx Panel indications
...
Guardant Health expands FDA-approved companion diagnostic use for HERNEXEOS
11 June 2026 - Precision oncology company Guardant Health Inc (Nasdaq:GH) announced on Thursday that the US Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic for Boehringer Ingelheim's HERNEXEOS (zongertin...
PharmaEssentia expands North American footprint with acquisition of Canadian partner FORUS Therapeutics
11 June 2026 - Taiwan-based biopharmaceutical company PharmaEssentia Corporation (TWSE:6446) announced on Thursday the acquisition of Canadian specialty pharmaceutical company FORUS Therapeutics Inc for USD36.5m, advancing its North American commerci...
FDA grants priority review for Genentech's Tecentriq in stage III dMMR/MSI-H colon cancer
11 June 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said on Thursday that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application for Tecentriq (atez...
Harbour BioMed IND for HBM7004 accepted by China's NMPA
...
Organon secures FDA approval expanding TOFIDENCE indications for CRS and paediatric COVID-19
10 June 2026 - US healthcare company Organon (NYSE:OGN) on Wednesday announced US Food and Drug Administration (FDA) approval of a supplemental Biologics License Application for TOFIDENCE (tocilizumab-bavi), an intravenous biosimilar to ACTEMRA (toci...
Sanofi halts phase 3 MOBILIZE study of riliprubart in CIDP
10 June 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Wednesday that it will stop the phase 3 MOBILIZE study evaluating riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (CIDP...